Genovis AB (publ.) (GENO.ST)
SEK 25.0
(2.04%)
SEK 25.0
(2.04%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 54 Million SEK | -38.19% |
| 2022 | 87.36 Million SEK | 7.48% |
| 2021 | 81.28 Million SEK | 41.13% |
| 2020 | 57.59 Million SEK | 2.61% |
| 2019 | 56.13 Million SEK | 66.4% |
| 2018 | 33.73 Million SEK | 54.61% |
| 2017 | 21.81 Million SEK | 24.8% |
| 2016 | 17.48 Million SEK | 61.74% |
| 2015 | 10.8 Million SEK | 124.17% |
| 2014 | 4.82 Million SEK | -33.23% |
| 2013 | 7.22 Million SEK | 97.54% |
| 2012 | 3.65 Million SEK | 177.64% |
| 2011 | -4.7 Million SEK | -687.69% |
| 2010 | 801.21 Thousand SEK | 849.92% |
| 2009 | -106.84 Thousand SEK | 87.81% |
| 2008 | -876.35 Thousand SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 2.5 Million SEK | -82.84% |
| 2024 Q1 | 14.57 Million SEK | 565.95% |
| 2023 Q1 | 67.09 Million SEK | 403.76% |
| 2023 Q2 | 28.14 Million SEK | -58.05% |
| 2023 Q3 | 26.02 Million SEK | -7.55% |
| 2023 FY | 54 Million SEK | -38.19% |
| 2023 Q4 | 2.18 Million SEK | -91.59% |
| 2022 Q2 | 22.15 Million SEK | -24.69% |
| 2022 FY | 87.36 Million SEK | 7.48% |
| 2022 Q3 | 22.47 Million SEK | 1.44% |
| 2022 Q4 | 13.31 Million SEK | -40.74% |
| 2022 Q1 | 29.41 Million SEK | -15.25% |
| 2021 Q3 | 14.19 Million SEK | -18.26% |
| 2021 Q4 | 34.71 Million SEK | 144.54% |
| 2021 FY | 81.28 Million SEK | 41.13% |
| 2021 Q1 | 15.01 Million SEK | -16.52% |
| 2021 Q2 | 17.36 Million SEK | 15.64% |
| 2020 Q3 | 15.48 Million SEK | 17.81% |
| 2020 Q4 | 17.98 Million SEK | 16.15% |
| 2020 Q1 | 10.43 Million SEK | -13.17% |
| 2020 FY | 57.59 Million SEK | 2.61% |
| 2020 Q2 | 13.14 Million SEK | 26.04% |
| 2019 FY | 56.13 Million SEK | 66.4% |
| 2019 Q4 | 12.01 Million SEK | -42.29% |
| 2019 Q1 | 11.14 Million SEK | 2.42% |
| 2019 Q2 | 12.16 Million SEK | 9.23% |
| 2019 Q3 | 20.81 Million SEK | 71.06% |
| 2018 Q2 | 7.69 Million SEK | 20.91% |
| 2018 FY | 33.73 Million SEK | 54.61% |
| 2018 Q4 | 10.87 Million SEK | 21.43% |
| 2018 Q3 | 8.95 Million SEK | 16.39% |
| 2018 Q1 | 6.36 Million SEK | -8.01% |
| 2017 FY | 21.81 Million SEK | 24.8% |
| 2017 Q4 | 6.91 Million SEK | 41.74% |
| 2017 Q2 | 5.88 Million SEK | 42.61% |
| 2017 Q1 | 4.12 Million SEK | 1619.61% |
| 2017 Q3 | 4.88 Million SEK | -17.07% |
| 2016 FY | 17.48 Million SEK | 61.74% |
| 2016 Q4 | -271.64 Thousand SEK | -105.48% |
| 2016 Q2 | 4.03 Million SEK | -53.96% |
| 2016 Q1 | 8.76 Million SEK | 434.5% |
| 2016 Q3 | 4.95 Million SEK | 22.72% |
| 2015 Q3 | 6.58 Million SEK | 50.96% |
| 2015 Q4 | -2.62 Million SEK | -139.82% |
| 2015 FY | 10.8 Million SEK | 124.17% |
| 2015 Q1 | 2.48 Million SEK | 2832.08% |
| 2015 Q2 | 4.36 Million SEK | 75.24% |
| 2014 Q3 | 999 Thousand SEK | -56.57% |
| 2014 FY | 4.82 Million SEK | -33.23% |
| 2014 Q1 | 1.61 Million SEK | 152.4% |
| 2014 Q2 | 2.3 Million SEK | 42.33% |
| 2014 Q4 | -91.06 Thousand SEK | -109.12% |
| 2013 Q1 | 1.56 Million SEK | 95.35% |
| 2013 FY | 7.22 Million SEK | 97.54% |
| 2013 Q4 | 640.25 Thousand SEK | -76.73% |
| 2013 Q3 | 2.75 Million SEK | 21.45% |
| 2013 Q2 | 2.26 Million SEK | 45.07% |
| 2012 FY | 3.65 Million SEK | 177.64% |
| 2012 Q2 | -1.67 Million SEK | -11.41% |
| 2012 Q3 | 1.24 Million SEK | 174.09% |
| 2012 Q4 | 799.59 Thousand SEK | -35.72% |
| 2012 Q1 | -1.5 Million SEK | -6.15% |
| 2011 Q1 | 174 Thousand SEK | -96.34% |
| 2011 Q2 | -842 Thousand SEK | -583.91% |
| 2011 Q3 | -1.32 Million SEK | -57.24% |
| 2011 Q4 | -1.41 Million SEK | -7.23% |
| 2011 FY | -4.7 Million SEK | -687.69% |
| 2010 Q2 | 165 Thousand SEK | 194.64% |
| 2010 FY | 801.21 Thousand SEK | 849.92% |
| 2010 Q1 | 56 Thousand SEK | -98.61% |
| 2010 Q4 | 4.75 Million SEK | 378.64% |
| 2010 Q3 | -1.7 Million SEK | -1135.15% |
| 2009 Q3 | -1.23 Million SEK | -13622.22% |
| 2009 Q1 | -1.8 Million SEK | 0.0% |
| 2009 FY | -106.84 Thousand SEK | 87.81% |
| 2009 Q4 | 4.02 Million SEK | 426.25% |
| 2009 Q2 | -9000.00 SEK | 99.5% |
| 2008 FY | -876.35 Thousand SEK | 0.0% |
| 2008 Q1 | -3.01 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 133.607% |
| Ziccum AB (publ) | -23.28 Million SEK | 331.903% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 84.407% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | -29.229% |
| Mendus AB (publ) | 28.48 Million SEK | -89.564% |
| Intervacc AB (publ) | -13.79 Million SEK | 491.482% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | -2387.379% |
| Active Biotech AB (publ) | -1.67 Million SEK | 3323.94% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | -442.015% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | -101.339% |
| Aptahem AB (publ) | 2.63 Million SEK | -1952.764% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | 1678.515% |
| Kancera AB (publ) | -1.96 Million SEK | 2848.142% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -70031.169% |
| Fluicell AB (publ) | 1.73 Million SEK | -3007.077% |
| Saniona AB (publ) | 11.78 Million SEK | -358.374% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 1155.325% |
| Biovica International AB (publ) | 6.87 Million SEK | -685.241% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 331.933% |
| AcouSort AB (publ) | 8.38 Million SEK | -543.712% |
| Xintela AB (publ) | 78 Thousand SEK | -69132.051% |
| Abliva AB (publ) | -35.66 Million SEK | 251.42% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 136.76% |
| Karolinska Development AB (publ) | 2.8 Million SEK | -1823.798% |
| OncoZenge AB (publ) | 3000.00 SEK | -1799933.333% |
| Amniotics AB (publ) | -1.93 Million SEK | 2897.979% |
| 2cureX AB (publ) | -37.48 Million SEK | 244.053% |
| CombiGene AB (publ) | -21.29 Million SEK | 353.637% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | 12866.194% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 95.22% |
| Camurus AB (publ) | 1.58 Billion SEK | 96.583% |
| Corline Biomedical AB | 28.38 Million SEK | -90.278% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 143.998% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 256.911% |
| I-Tech AB | 27.56 Million SEK | -95.897% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 23.89% |
| Cyxone AB (publ) | 2.61 Million SEK | -1968.211% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | -1486.865% |
| Biosergen AB | -456 Thousand SEK | 11942.325% |
| Cantargia AB (publ) | -3.45 Million SEK | 1664.793% |
| NextCell Pharma AB | -43.74 Million SEK | 223.436% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | 687.35% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | -381.366% |
| Nanologica AB (publ) | -76 Thousand SEK | 71153.947% |
| SynAct Pharma AB | -778 Thousand SEK | 7041.003% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | 28079.793% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | 517.9% |
| Lipum AB (publ) | 53 Thousand SEK | -101788.679% |
| BioInvent International AB (publ) | 71.46 Million SEK | 24.433% |
| Alzinova AB (publ) | 19.87 Million SEK | -171.717% |
| Oncopeptides AB (publ) | 36.29 Million SEK | -48.767% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -3591.064% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | 360106.667% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | -3156.996% |
| Simris Alg AB (publ) | 2 Million SEK | -2590.633% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | 1608.408% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | -52.597% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | 5247.855% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | -1623.62% |